The possible treatments options for metastatic hormone-sensitive prostate cancer (mHSPC)
have dramatically increased during the last years. The old backbone, which androgen …

Background The cornerstone of standard treatment for patients with primary bone metastatic
prostate cancer (mPCa) is androgen deprivation therapy (ADT). Retrospective studies …

Context The current standard of care for metastatic prostate cancer (PCa) is androgen
deprivation therapy (ADT) plus either docetaxel or abiraterone. Growing evidence suggests …

Background Androgen deprivation therapy (ADT) represents the standard treatment for
hormone-naïve prostate cancer with systemic metastases (mPCA). The role of radical …

Objectives To investigate the role of cytoreductive radical prostatectomy in addition to
standard of care for patients with newly diagnosed metastatic prostate cancer. Materials and …

Context: There is a growing interest about the role of radical prostatectomy (RP) in local
cancer control in oligometastatic prostate cancer (PCa). Purpose: To evaluate the …

Purpose Amongst the unanswered questions regarding prostate cancer (PCa), the optimal
management of oligometastatic disease remains one of the major concerns of the scientific …

The potential oncological benefit for radical treatment in the setting of oligometastatic
prostate cancer has been under investigation and is frequently discussed. We carried out a …

Background The prognostic value of circulating tumor cells (CTCs) in patients with hormone-
naïve oligometastatic prostate cancer (HNoMPC) undergoing cytoreductive radical …

Patients with low-volume/low-risk metastatic prostate cancer (mPCA), good response to
neoadjuvant androgen deprivation therapy and a good Eastern Cooperative Onology Group …